— Christine M. Kukka, Project Manager, HBV Advocate
A global study followed 280 patients infected with HBV, 99% of whom
were resistant to lamivudine (Epivir-HBV), 12% were resistant to
entecavir and 1.8% were resistant to adefovir (Hepsera) due to previous
treatments. Tenofovir (Viread) with or without emtricitabine was
effective in all drug-resistant patients.
After 96 weeks of treatment with tenofovir or a
combination of tenofovir plus emtricitabine, researchers reported they
found no development of tenofovir resistance in the HBV of 18 patients
who had their HBV sequenced.
Researchers, writing in the June issue of the journal of Clinical Gastroenterology and Hepatology, noted there appeared to be no additional benefit from the tenofovir-emtricitabine combination, compared to tenofovir alone.
Source: www.ncbi.nlm.nih.gov/pubmed/24929235
Labels: lamivudine resistance, tenofovir